Pharming Group (NASDAQ:PHAR) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Pharming Group (NASDAQ:PHAR) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $14.00 price objective on the stock.

Several other equities analysts have also recently commented on PHAR. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, October 24th. Oppenheimer reduced their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Stock Up 7.0 %

Shares of PHAR stock opened at $8.26 on Monday. Pharming Group has a 12 month low of $6.65 and a 12 month high of $13.20. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market cap of $560.47 million, a PE ratio of -31.78 and a beta of 0.05. The stock has a 50 day moving average of $8.21 and a 200-day moving average of $8.14.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.